Tranexamic acid did not increase complications in patients with intertrochanteric fracture

Results showed tranexamic acid administration was not associated with increased mortality, deep venous thrombosis, pulmonary embolism, myocardial infarction or stroke in high-risk patients with intertrochanteric hip fractures.
To evaluate the safety and efficacy of tranexamic acid (TXA) for patients with surgically treated intertrochanteric hip fractures, Steven B. Porter, MD, and investigators at the Mayo Clinic in Jacksonville, Florida analyzed 1,147 patients who underwent surgery for these fractures between 2015 and 2019. Among the cohort, 800 patients had surgery performed without TXA and

Results showed tranexamic acid administration was not associated with increased mortality, deep venous thrombosis, pulmonary embolism, myocardial infarction or stroke in high-risk patients with intertrochanteric hip fractures.
To evaluate the safety and efficacy of tranexamic acid (TXA) for patients with surgically treated intertrochanteric hip fractures, Steven B. Porter, MD, and investigators at the Mayo Clinic in Jacksonville, Florida analyzed 1,147 patients who underwent surgery for these fractures between 2015 and 2019. Among the cohort, 800 patients had surgery performed without TXA and